Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor cell membrane fusion refers to the process by which the plasma membranes of two cells—often a tumor cell and another cell type—merge, resulting in a hybrid cell that contains genetic and cytoplasmic material from both parent cells. This process is mediated by viral envelope glycoproteins known as F proteins (fusion proteins), originally characterized in paramyxoviruses. These F proteins undergo proteolytic cleavage to expose a hydrophobic fusion peptide that inserts into target membranes, leading to conformational changes that bring cellular membranes into close proximity and facilitate fusion. Engineered hyperfusogenic variants of viral F proteins are being developed as cancer therapeutics to induce extensive tumor cell-cell fusion, leading to immunogenic cell death.
Induces membrane merger between adjacent cells via dehydration, hemifusion, pore opening, and cytoplasmic mixing, leading to cell death.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Viral Fusion Protein (F Protein) Mediated Tumor Cell Membrane Fusion (F Protein).